Health Care & Life Sciences » Pharmaceuticals | Innovus Pharmaceuticals Inc.

Innovus Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
6.60
1,030.10
735.70
4,818.60
8,816.30
23,990
Cost of Goods Sold (COGS) incl. D&A
18.60
292.10
630.60
1,083.10
1,848.30
4,325
Gross Income
12.00
738.00
105.10
3,735.50
6,968.00
19,665
SG&A Expense
3,877.00
4,522.70
3,620.30
9,569.40
12,067.20
25,357
EBIT
3,888.90
3,784.60
-
5,833.90
5,099.20
5,692
Unusual Expense
-
510.10
282.60
1,204.80
522.60
1,128
Non Operating Income/Expense
-
-
8.50
1.70
6.90
13
Interest Expense
67.20
532.20
1,153.40
6,661.70
872.20
1,446
Pretax Income
3,956.20
4,827.00
4,959.70
13,698.80
6,500.90
8,279
Income Tax
-
-
757.00
2.40
3.20
-
Consolidated Net Income
3,956.20
4,827.00
4,202.60
13,701.20
6,504.10
8,279
Net Income
3,956.20
4,827.00
4,202.60
13,701.20
6,504.10
8,279
Net Income After Extraordinaries
3,956.20
4,827.00
4,202.60
13,701.20
6,504.10
8,279
Net Income Available to Common
3,956.20
4,827.00
4,202.60
13,701.20
6,504.10
8,279
EPS (Basic)
0.23
0.20
0.08
0.15
0.04
4.16
Basic Shares Outstanding
17,329.90
24,384.00
52,517.50
94,106.40
157,933.50
1,989.10
EPS (Diluted)
0.23
0.20
0.08
0.15
0.04
4.16
Diluted Shares Outstanding
17,329.90
24,384.00
52,517.50
94,106.40
157,933.50
1,989.10
EBITDA
3,870.30
3,607.20
2,935.50
5,204.00
4,457.30
5,004

About Innovus Pharmaceuticals

View Profile
Address
8845 Rehco Road
San Diego California 92122
United States
Employees -
Website http://www.innovuspharma.com
Updated 07/08/2019
Innovus Pharmaceuticals, Inc. engages in the commercialization, licensing, and development of non-prescription medicine, and consumer care products for health and vitality, and respiratory diseases. It also provides packaged healthcare solutions through over-the-counter, medicines and consumer and health products, which it market directly or through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through on-line channels, retailers and wholesalers. The company business model leverages the ability to acquire and in-license commercial products that are supported by scientific, and or clinical evidence, place them through it existing supply chain, retail and on-line channels.